KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease

Acronyms and Abbreviations

4-D Die Deutsche Diabetes Dialyse Studie
4S Scandinavian Simvastatin Survival Study
ACCORD Action to Control Cardiovascular Risk in Diabetes
ACVD Atherosclerotic Cardiovascular Disease
AFCAPS/TexCAPS Air Force/Texas Coronary Atherosclerosis Prevention Study
AHA American Heart Association
AJKD American Journal of Kidney Diseases
ALERT Assessment of Lescol in Renal Transplantation
ALLHAT Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial
ALLIANCE Aggressive Lipid Lowering Initiation Abates New Cardiac Events
ASPEN Atorvastatin as Prevention of Coronary Heart Disease Endpoints in Patients with Non-Insulin-Dependent Diabetes Mellitus
AST American Society of Transplantation
ATP III Adult Treatment Panel III
AUC Area under the (concentration-time) curve
AZA Azathioprine
BIP Bezafibrate Infarction Prevention
CARDS Collaborative Atorvastatin Diabetes Study
CARE Cholesterol and Recurrent Events
CHD Coronary Heart Disease
CHOL Cholesterol
CK Creatinine phosphokinase
CKD Chronic kidney disease
CMV Cytomegalovirus
Cr Creatinine (serum)
CsA CyclosporineA
CVD Cardiovascular disease
DOQI Dialysis Outcomes Quality Initiative
EDTA European Dialysis and Transplantation Association
EPA Eicosapentaenoic acid (20:n-3)
ESRD End-stage renal disease
EXCEL Expanded Clinical Evaluation of Lovastatin
FIELD Fenofibrate Intervention and Event Lowering in Diabetes
FMC Fresenius Medical Care
GFR Glomerular filtration rate
HD Heart disease
HDL High-density lipoprotein
HPS The Heart Protection Study
IDEAL Incremental Decrease in Endpoints Through Aggressive Lipid Lowering
IDL Intermediate-density lipoproteins
KDOQI Kidney Disease Outcomes Quality Initiative
LDL Low-density lipoprotein
LIPID Long-Term Intervention with Pravastatin in Ischaemic Disease
LMWH Low molecular weight heparin
Lp(a) Lipoprotein (a)
MI Myocardial infarction
MIRACL Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering
MMF Mycophenolate mofetil
MRC Medical Research Council
N Number (of data points)
NCEP National Cholesterol Education Program
NCEP-C National Cholesterol Education Program-Children
NHANES National Health and Nutrition Examination Survey
NHLBI National Heart, Lung and Blood Institute
NIH National Institutes of Health
NKF National Kidney Foundation
NKF-KDOQI National Kidney Foundation Kidney Disease Outcomes Quality Initiative
NS Nephrotic syndrome
PDAY Pathobiological Determinants of Atherosclerosis in Youth
PREVEND IT Prevention of REnal and Vascular ENdstage Disease Intervention Trial
PRINCE Pravastatin Inflammation/C-Reactive Protein Evaluation
PROSPER Prospective Study of Pravastatin in the Elderly at Risk
PROVE IT Pravastatin or Atorvastatin in Evaluation and Infection Therapy
SEARCH Study Evaluating Additional Reductions in Cholesterol and Homocysteine
SHARP The Study of Heart and Renal Protection
SPARCL Stroke Prevention by Aggressive Reduction in Cholesterol Levels
TG, TRIG Triglycerides
TLC Therapeutic lifestyle changes
TNT Treating to New Targets
USFDA United States Food and Drug Administration
VA-HIT Veterans Administration High-Density Lipoprotein Cholesterol Intervention Trial
VLDL Very low-density lipoprotein
WOSCOPS West of Scotland Coronary Prevention Study